Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-874 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Regimen A | EXPERIMENTAL | One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen B | EXPERIMENTAL | One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein |
| Regimen C | EXPERIMENTAL | One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen D | EXPERIMENTAL | One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle |
| Regimen E | EXPERIMENTAL | 700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein |
| Name | Type | Description |
|---|---|---|
| ABT-874 | DRUG | See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively. |
Inclusion Criteria: * Subjects must be healthy Exclusion Criteria: * Subjects who are not healthy, enrolled in another study, or who have received ABT-874 previously.
ABT-874 is an investigational small molecule being developed by Abbott Laboratories. It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers, and its therapeutic area is classified as Other. It is not approved and remains in clinical trials.
ABT-874 is being studied for use in healthy volunteers. The Phase 1 trial is a bioavailability study conducted in healthy individuals. The drug's intended therapeutic indication has not been specified beyond this early-stage research context.
ABT-874 is being developed by Abbott Laboratories, which trades under the ticker ABT. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy volunteers.
ABT-874 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved for any use.
ABT-874 has one completed clinical trial, NCT00870948, titled 'Phase 1 BA Study, Single Center With Healthy Volunteers.' This was a Phase 1, controlled, randomized study conducted in the United States with 75 healthy participants aged 18 years and older.
ABT-874 is not known to have alternative names. It is identified solely by its development code ABT-874 in clinical trial records.